Periodic Reporting for period 2 - ULTIMATE (The best online drug discovery platform, Building the Ultimate chemical database for drug discovery)
Période du rapport: 2018-08-01 au 2019-07-31
The mission of our company, mcule.com Ltd., is to provide the best on-line drug discovery platform. In the ULTIMATE project we aim to create virtual compounds of high pharmaceutical interest, which are not yet synthesized, but predicted to be synthesizable with low effort for a reasonable price. The objective is to develop the chemical database of 500 million molecules, the ""ULTIMATE database”, in which the “virtual compounds” will be easily accessible for clients, as they can be synthesized by easy reactions, at affordable price, in reasonable time.
"
From the technical point of view, we developed the artificial chemist algorithm, which generates (enumeration) the virtual compounds in the Ultimate database using compounds from our supplier partners and selected robust chemical reactions. We also introduced property based prefiltering steps in the enumeration process to produce compounds only in the relevant mass-logP space. The compounds generated from these scaffolds represent exceptional high novelty. As result, we gained a database with 480,705,509 unique compounds with acceptable feasibility. Currently, 412,678,723 compounds are searchable Ultimate web application at https://ultimate.mcule.com. We made the IT system architecture, data model, and the API of the ULTIMATE database back-end as well, the front-end. We set-up the physical framework and performed several IT system tests, which satisfied our expectations. Continuous validation and improvement of the Ultimate database and the reaction rules for its generation was continuously done during the project in collaboration with chemical supplier partners and chemical experts. As a result of the overall validation, we concluded that the ULTIMATE database has all desired properties and functions and it is superior in terms of both coverage of the chemical space and the number of molecules to existing commercial databases.
From the commercial point of view, we updated our market analysis. We prepared a detailed business plan using Business Modell Canvas method both for the exploitation of Ultimate project results. We made considerable improvements of our logistic and financial framework to make possible the fulfilment of the increased number of orders generated by ULTIMATE project. We defined a commercialisation roadmap, including both technical and business activities to be carried out until the planned product launch as well as afterwards. We defined the marketing mix for the exploitation of the Ultimate project results as well as the strategy to promote our growth.
As the impact of the project, the efficiency of the drug discovery will increase. The use of the ULTIMATE database will expectedly double the delivery rates in hit-to-lead and in lead-to-clinic phases of drug discovery. This will divide into quarter the number of molecules required to be experimentally tested in early drug discovery, thus reducing considerably the required time of finding a new drug. This will be a major benefit for pharmaceutical companies, and also for the society.
Regarding our company, the ULTIMATE project will promote our growth by increasing considerably our market share as a compound sourcing solution supplying also virtual compounds at high reliability.